Breast cancer is predominantly recognized as a condition affecting women, however, male breast cancer (MBC), despite its rarity, represents a significant and serious malignancy in men. Accounting for approximately 1% of all breast cancer cases, MBC is often diagnosed at a later stage compared to female breast cancer, primarily due to a lack of awareness and the absence of screening programs tailored for men. This delayed diagnosis typically results in poorer prognoses and more limited treatment options. Over the past decade, there has been a notable increase in research and awareness surrounding MBC. This surge is largely driven by the recognition of its unique epidemiological and biological characteristics, which are distinct from those of female breast cancer. However, due to its low incidence, many aspects of MBC, including its etiology, clinical presentation, and optimal treatment strategies, remain inadequately understood. This paper aims to provide a comprehensive review of MBC by examining its incidence, mortality rates, and epidemiological characteristics on a global scale. Additionally, it explores the economic burden associated with the disease, identifies key risk factors, and discusses current preventive measures. Finally, the paper will offer insights into future research directions and potential advancements in the diagnosis and treatment of MBC.

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by challenging early diagnosis, limited therapeutic options, and a poor prognosis. Diabetes mellitus, marked by altered glucose metabolism, has emerged as a significant risk factor for PDAC development, highlighting a complex, bidirectional pathogenic relationship. This review systematically examines the intricate interactions between diabetes and PDAC, emphasizing their shared pathophysiological mechanisms. A comprehensive understanding of these mechanisms can inform the development of targeted therapeutic strategies, potentially improving patient outcomes by concurrently managing diabetes and pancreatic cancer. We further evaluate current biomarker screening approaches for PDAC within diabetic subpopulations, assess the effectiveness of screening programs among high-risk groups, and propose practical strategies for the early identification and monitoring of PDAC. Early detection in diabetic individuals through targeted biomarker screening followed by timely therapeutic intervention may significantly reduce mortality, improve survival rates, and extend patient longevity. In conclusion, an integrated approach combining early diagnosis, targeted treatments, and a detailed understanding of the underlying pathogenesis represents the most promising strategy for enhancing clinical outcomes and survival among diabetic patients diagnosed with pancreatic cancer.